AUS
NZ
UK
CA
USA
IND
Healthcare
Why Did Zynex Receive FDA Clearance for Its New Device?
October 24, 2024 03:12 PM PDT| By Team Kalkine MediaHighlights,Zynex Inc. reports an increase in orders for its pain management devices.,The company secures FDA clearance for its new TensWave device.,Zynex aims to diversify revenue through orthopedic products and expand its salesforce.,Zynex Inc., a k...
Why Did Merck’s KEYTRUDA Secure Two New EU Approvals?
October 24, 2024 02:11 PM PDT| By Team Kalkine MediaHighlights,Merck gains two new EU approvals for KEYTRUDA in gynecologic cancers.,Approvals cover treatments for advanced endometrial and cervical cancers.,Clinical trials show significant benefits in disease progression and survival.,Merck, a leading...
Strong Earnings Propel Laboratory Co. of America Stock Higher
October 24, 2024 12:43 PM PDT| By Team Kalkine MediaHeadlines,Laboratory Co. of America experiences significant stock increase,Strong earnings exceed expectations, boosting market confidence,Upcoming dividend highlights commitment to shareholder returns,Laboratory Co. of America Holdings,(NYSE:LH),wit...
Riverwater Partners LLC Expands Ownership in Haemonetics Co. (NYSE:HAE)
October 24, 2024 04:27 AM PDT| By Team Kalkine MediaHighlights,Significant Increase in Holdings: Riverwater Partners LLC raised its stake in Haemonetics Co. by 185% in Q3 2024, acquiring over 29,000 additional shares.,Institutional Activity: Other institutional investors also adjusted their positions,...
What Is Driving Sangamo Therapeutics' Recent Momentum?
October 23, 2024 12:35 PM PDT| By Team Kalkine MediaHighlights,Sangamo Therapeutics experiences significant momentum in share price within the biotech sector.,Despite recent gains, the company faces concerns over its price-to-sales ratio compared to industry norms.,Revenue trends reveal challenges, bu...
How Is OKYO Pharma Addressing the Unmet Need for NCP Treatment?
October 23, 2024 12:20 PM PDT| By Team Kalkine MediaHighlights,OKYO Pharma Ltd begins Phase 2 trial of OK-101 for neuropathic corneal pain (NCP).,The trial targets a chronic condition currently lacking FDA-approved treatments.,The study involves a randomized, placebo-controlled format to evaluate safe...
Pfizer (PFE) Gains Strong Attention with New Rating from Cantor Fitzgerald
October 23, 2024 11:41 AM PDT| By Team Kalkine MediaHeadlines,Pfizer receives positive recognition from Cantor Fitzgerald.,Multiple research firms adjust their outlook on Pfizer.,Analysts maintain favorable outlook for Pfizer’s future.,Pfizer,(NYSE:PFE),has earned renewed attention after Cantor Fitzge...
Artivion Experiences Strong Surge: Analyst Upgrades Drive Confidence
October 23, 2024 11:35 AM PDT| By Team Kalkine MediaHeadlines,Artivion shares surged following analyst upgrades.,Research firms forecast optimistic outlook for the company's stock performance.,Increased coverage and positive assessments boost market confidence.,Artivion,(NYSE:AORT),shares experienced...
Envista Receives Revised Price Target from Stifel Nicolaus
October 23, 2024 11:33 AM PDT| By Team Kalkine MediaHeadlines,Stifel Nicolaus raises Envista's target price to $21.00.,Multiple firms adjust their ratings on Envista.,Revised outlook suggests positive momentum for the company.,Envista,(NYSE:NVST),has received a revised price target from Stifel Nicolau...
Alto Neuroscience (NYSE: ANRO) Reports Phase 2b Study Results for ALTO-100, Faces Setback in Major Depressive Disorder Treatment
October 22, 2024 10:18 PM PDT| By Team Kalkine MediaHighlights:,ALTO-100 fails to meet primary endpoint in Phase 2b study for major depressive disorder (MDD).,Despite the setback, the treatment shows a favorable safety and tolerability profile.,Alto Neuroscience maintains a strong cash position to sup...
Can Alto Neuroscience Recover After ALTO-100 Trial Results?
October 22, 2024 02:46 PM PDT| By Team Kalkine MediaHighlights,Alto Neuroscience reports Phase 2b trial results for its drug candidate ALTO-100 in treating major depressive disorder.,The trial did not achieve its primary endpoint, but the drug maintained a positive safety profile.,The company continue...
Will NeoGenomics' Approval Boost Its Market Position?
October 22, 2024 02:35 PM PDT| By Team Kalkine MediaHighlights,NeoGenomics gains conditional approval for advanced cancer tests in New York.,The new assays offer enhanced diagnostic value for various solid tumors.,Approval expands NeoGenomics’ reach to more healthcare providers and patients in New Yor...
ENDRA Life Sciences Advances Liver Health Technology in Germany
October 22, 2024 01:13 PM PDT| By Team Kalkine MediaHighlights,ENDRA Life Sciences launches a clinical study for its TAEUS liver system in Germany.,The study will evaluate TAEUS’ effectiveness in measuring liver fat against MRI-PDFF.,The initiative supports broader adoption and regulatory approval eff...
Charles River Laboratories Faces Analyst Scrutiny Amid Stock Decline
October 22, 2024 09:20 AM PDT| By Team Kalkine MediaHeadlines,Charles River Laboratories Faces Decline Amid Analyst Downgrades,Stock Performance Reflects Mixed Analyst Sentiment,Adjustments in Price Targets Impact CRL's Recent Trading,Charles River Laboratories International,(NYSE:CRL),saw a 4.9% decl...
Molecular Partners and Orano Med Present Enhanced Preclinical Data for MP0712 at EANM 2024
October 22, 2024 04:11 AM PDT| By Team Kalkine MediaHighlights,Molecular Partners AG and Orano Med presented promising preclinical data for their Radio-DARPin Therapeutic candidate, MP0712, at the EANM Congress 2024.,MP0712 demonstrated dose-dependent efficacy, favorable safety profiles, and high spec...
GRI Bio Confirms Exercise of Warrants
October 22, 2024 04:09 AM PDT| By Team Kalkine MediaHighlights,GRI Bio has entered into definitive agreements to exercise existing warrants, allowing the purchase of 762,236 shares at a reduced price.,The company will issue new unregistered Series D-1 and D-2 warrants in conjunction with this exercise...
Interim Results Indicate Progress in Phase 3 ENSURE Program of Vidofludimus Calcium
October 22, 2024 04:06 AM PDT| By Team Kalkine MediaHighlights,Immunic, Inc. received a positive recommendation from the Independent Data Monitoring Committee for its phase 3 ENSURE program, assessing vidofludimus calcium for relapsing multiple sclerosis.,The ENSURE program remains on schedule for com...
Noteworthy US Penny Stocks Highlighted for October 2024
October 22, 2024 03:49 AM PDT| By Team Kalkine MediaHighlights,Mixed performance in the U.S. stock market has led to renewed interest in penny stocks.,A selection of penny stocks exhibiting strong financial health is available for exploration.,Companies in diverse sectors, including transportation, bi...
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Pioneers Noninvasive Solutions for Sleep Disorders
October 22, 2024 01:32 AM PDT| By Team Kalkine MediaHighlights:,Vivos Therapeutics receives new AMA CPT codes for enhanced insurance reimbursement of OSA treatments.,FDA clears Vivos CARE oral devices for effective treatment of sleep apnea in children and adults.,Over 31,000 patients treated globally...
Could Elevai Biosciences' EL-32 Be Missing the Mark on Addressing Obesity?
October 21, 2024 03:36 PM PDT| By Team Kalkine MediaHighlights,Elevai Biosciences has released data on a dual-action blocker, EL-32, for muscle and fat composition.,Preclinical studies on aged mice indicated improved strength, motor function, and body composition.,Further animal studies are planned fo...
